SCHEMBL3003105

SCHEMBL3003105

COc1cccc(-c2csc(N3CCN(S(=O)(=O)c4cc(OC)ccc4OC)CC3)n2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.70
HSD17B10 Q99714 4/20 0.70
RECQL P46063 2/20 0.70
USP2 O75604 2/20 0.70
ALDH1A1 P00352 8/20 0.58
LMNA P02545 7/20 0.58
KMT2A Q03164 5/20 0.58
HTT P42858 4/20 0.58
MAPK1 P28482 4/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
TP53 P04637 2/20 0.58
GAA P10253 1/20 0.58
HPGD P15428 1/20 0.57
MEN1 O00255 3/20 0.56
TSHR P16473 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
KDM4E B2RXH2 1/20 0.55
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C9 P11712 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003497 0.94 MAPT (0.62) MAPTHSD17B10RECQLUSP2ALDH1A1
SCHEMBL3008783 0.93 MAPT (0.61) MAPTHSD17B10RECQLUSP2ALDH1A1
SCHEMBL3015434 0.93 MAPT (0.66) MAPTHSD17B10RECQLUSP2ALDH1A1
SCHEMBL3013945 0.93 MAPT (0.66) MAPTHSD17B10RECQLUSP2ALDH1A1
SCHEMBL3007184 0.93 MAPT (0.61) MAPTHSD17B10RECQLUSP2ALDH1A1
SCHEMBL3012508 0.92 MAPT (0.70) MAPTHSD17B10RECQLUSP2ALDH1A1
SCHEMBL3008597 0.92 MAPT (0.59) MAPTHSD17B10RECQLUSP2ALDH1A1
SCHEMBL3003931 0.91 MAPT (0.60) MAPTHSD17B10RECQLUSP2ALDH1A1
SCHEMBL3012041 0.91 POLB (0.59) MAPTHSD17B10RECQLUSP2ALDH1A1
SCHEMBL3649055 0.89 MAPT (0.61) MAPTHSD17B10RECQLUSP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.